Thompson Investment Management’s Standard BioTools LAB Stock Holding History

Thompson Investment Management’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-16,200	Closed	-$65K	–	179
2017 Q2	$65K	Hold	16,200	–	–	0.01%	176
2017 Q1	$92K	Hold	16,200	–	–	0.02%	176
2016 Q4	$118K	Hold	16,200	–	–	0.02%	176
2016 Q3	$130K	Hold	16,200	–	–	0.03%	176
2016 Q2	$146K	Hold	16,200	–	–	0.03%	170
2016 Q1	$131K	Hold	16,200	–	–	0.03%	169
2015 Q4	$175K	Hold	16,200	–	–	0.04%	167
2015 Q3	$131K	Buy	+16,200	New	+$255K	0.03%	165
2015 Q2	–	Sell	-7,200	Closed	-$303K	–	171
2015 Q1	$303K	Hold	7,200	–	–	0.06%	140
2014 Q4	$243K	Buy	+7,200	New	+$204K	0.05%	154

Other funds holding LAB

LCS

Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Thompson Investment Management's LAB Position: Q3 2017 in Review

Thompson Investment Management sold out of Standard BioTools (LAB) in Q3 2017, closing a stake of 16,200 shares — an estimated $65K sold.

Thompson Investment Management first reported a position in LAB in Q4 2014 and held it in 10 quarters. The position peaked at $303K in Q1 2015. 80 funds tracked by Wall St. Rank hold LAB as of Q3 2017.

Thompson Investment Management reported no remaining Standard BioTools position as of Q3 2017 after selling out during the quarter.
Thompson Investment Management sold 16,200 Standard BioTools shares in Q3 2017, an estimated $65K.
Thompson Investment Management first reported a position in Standard BioTools in Q4 2014 and held it in 10 quarters.
Thompson Investment Management's Standard BioTools position peaked at $303K in Q1 2015.
80 funds tracked by Wall St. Rank held Standard BioTools as of Q3 2017.

Based on Thompson Investment Management's 13F filing for Q3 2017, filed 7 Nov 2017.